Evaluation of ONYX in ENDOVASCULAR Treatment of Cerebral AVMs — cAVM

Cerebral Arteriovenous Malformations Clinical Trial

Official title:
Evaluation of ONYX in ENDOVASCULAR Treatment of Cerebral AVMs. Prospective, Multi-center and Observational French Study

Status Completed

Clinical Trial Summary

To assess safety and efficacy of ONYX treatment for cAVM:

Clinical Trial Description

The main objective of this study is to assess the safety at 1 month after any embolization session and the efficacy at: - 12 months post last embolization in case of treatment with embolization only - 12 months after additional treatment with neurosurgery - 36 months after additional treatment with radiosurgery ;

Study Design

Related Conditions & MeSH terms

Arteriovenous Malformations
Cerebral Arteriovenous Malformations
Congenital Abnormalities
Intracranial Arteriovenous Malformations

Clinical Trial Details

NCT number	NCT02180958
Study type	Observational [Patient Registry]
Source	Medtronic Neurovascular Clinical Affairs
Contact
Status	Completed
Phase
Start date	July 2014
Completion date	October 2021

View Details

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT03676868` - Biology of Cerebral Arteriovenous Malformations and Prognosis of Cerebral Arteriovenous Malformations
	Recruiting	`NCT06259292` - Comprehensive HHT Outcomes Registry of the United States (CHORUS)
	Completed	`NCT02602990` - Treatment of Cerebral Arteriovenous Malformations With SQUID™ Liquid Embolic Agent